Annual Reports in Medicinal Chemistry

Erscheinungsjahr 2010
ISBN: 978-0-12-380902-5
Verlag: William Andrew Publishing

Buch, Englisch, 648 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 860 g

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Zielgruppe

For medicinal, pharmaceutical, and organic chemists

Autoren/Hrsg.

Weitere Mitwirkende

Macor, John E.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
• Naturwissenschaften Chemie Organische Chemie Biochemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

Section I: Central Nervous System Diseases - ROBICHAUD

- Voltage-Gated Calcium Channel Antagonists for the Central Nervous System

James C. Barrow and Joseph L. Duffy

- Recent Developments in Glycine Transporter-1 Inhibitors

Christopher L. Cioffi, Shuang Liu and Mark A.Wolf

- Modulators of Transient Receptor Potential Ion Channels

Rajagopal Bakthavatchalam and S. David Kimball

- Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships

Christopher L. Shaffer

Section II: Cardiovascular and Metabolic Diseases - STAMFORD

- High Affinity Niacin Receptor GPR109A Agonists

Hong C. Shen and Steven L. Colletti

- Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors

Matthew P. Bourbeau, John G. Allen, and Wei Gu

- Enzymatic Targets in the Triglyceride Synthesis Pathway

Dmitry O. Koltun and Jeff Zablocki

- Inhibitors of HIF Prolyl Hydroxylases

Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan

Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein

- Opioid Receptor Antagonists for Gastrointestinal Dysfunction

R. William Hipkin and Roland E. Dolle

- CFTR Modulators for the Treatment of Cystic Fibrosis

Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis

- Targeting B-cells in inflammatory disease

Kevin S. Currie

- Modulators of Toll-Like Receptor (TLR) Signaling

Mark Spyvee, Lynn Hawkins, and Sally Ishizaka

Section IV: Oncology - McAlpine

- Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)

Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo

- Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology

Philip Jones

- Epigenetic Targets and Cancer Drug Discovery

Patrick M. Woster, Ph.D

Section V: Infectious Diseases - Primeau

- HIV-1 Integrase Strand Transfer Inhibitors

Brian A. Johns

- Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites

Robert T. Jacobs and Charles Ding

- Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis

Vincent Gerusz

Section VI: Topics in Biology - LOWE

- Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer's Disease

Dr. Robert B. Nelson

- Targeting Methyl Lysine

Stephen V. Frye, Tom Heightman and Jian Jin

- Chemical Proteomic Technologies for Drug Target Identification

Kieran F. Geoghegan and Douglas S. Johnson

- NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development

Raj N. Misra

Section VII: Topics in Drug Design and Discovery - DESAI

- Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks

Martin P. Edwards and David A. Price

- Reducing the Risk of Drug Attrition Associated with Physicochemical Properties

Paul D. Leeson and James R. Empfield

- Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update

Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski

- The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties

Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman

- Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property

Charles J. Andres, Jr. and Richard L. Treanor

Section VIII: Trends and Perspectives

- To Market, To Market - 2009

Shridhar Hegde and Michelle Schmidt